

EMERGING ROLE OF DNA VACCINE

¹R. Pon Preeja, ²Lakshminarayanan Arivarasu

¹Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu India

²Assistant Professor, Department of Pharmacology, Saveetha Dental College and hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.

¹151801061.sdc@saveetha.com

²lakshmin.sdc@saveetha.com

ABSTRACT:

DNA vaccination is a strategy for securing against illness by infusion With hereditary designed plasmid containing the DNA sequences encoding the antigen against which a resistant reaction is looked for so cell straightforwardly produce and immunised creating a defensive Immunological response. DNA immunisations have been named “Third generation of vaccines” the ongoing effective vaccination of subjects against the scope of an irresistible specialist and a few tumour models of illness with plasmid DNA vouches for the amazing idea of this progressive in methodology in vaccinology. DNA antibodies evoke defensive CD 8+ immune system microorganism reaction. Malarial naive volunteers who were inoculated with plasmid DNA encoding a malarial protein create an antigen-explicit hereditary confined CD8+ lymphocytes subordinate CTLs. Reactions were coordinated against each of the 10 peptides tried and were limited by six human lymphocytes antigen (HLA) class one alleles. DNA encoding a mycobacterium antigen gives an effective and straightforward strategy for producing defensive invulnerability and that this methodology might be helpful for characterising the defensive antigens of Mycobacterium tuberculosis prompting the improvement of progressively successful antibody .The immunisation with DNA encoding Mycobacterium antigen generates protective immunity. In future DNA vaccines can be applied to boost the immune system.

KEYWORDS: CD8+ , DNA vaccine, HLA, immunisation, plasmid DNA,

INTRODUCTION:

DNA vaccination is a strategy for securing against illness by infusion With hereditary designed plasmid containing the DNA sequences encoding the antigen against which a resistant reaction is looked for, the cell straightforwardly produces and immunises creating a defensive Immunological response (Services *et al.*, 1996). DNA immunisations have potential points of interest over conventional vaccines including the capacity to prompt a more extensive scope of safe reaction (Robinson and Pertmer, 2000; Anitha and Ashwini, 2017). The immunisation with DNA encoding mycobacterial antigen gives a productive and straightforward strategy for creating defensive in susceptibility and that this method might be helpful for characterising the defensive antigen of M.tuberculosis prompting the advancement of an increasingly viable antibody (Huygen *et al.*, 1996). DNA immunisations have been named “Third generation of vaccines” the ongoing effective vaccination of subjects against the scope of an irresistible specialist and a few tumour models of illness with plasmid DNA vouches for the amazing idea of this progressive in methodology in vaccinology (Baker *et al.*, 2001).

DNA antibodies have potential points of interest over conventional vaccines including its ability to induce wider range of immunity (Kumar and Sercarz, 1996). Antibacterial properties of nanoparticles were assessed against Escherichia coli ,Bacillus subtilis, Staphylococcus aureus, Bacillus cereus and Klebsiella pneumonia utilizing agarwell dispersion technique (Ezhilarasan, 2018; Karthiga, Rajeshkumar and

Annadurai, 2018). Micro RNA (miRNA) plays a vital role in cellular growth, differentiation, apoptosis, and immune response, and therefore, deregulation of miRNA is examined as a sign of oral carcinogenesis (Maheswari *et al.*, 2018). Nanotechnology is associated with nano-meter sized objects. Living organisms are composed of cells. These cell parts, however, are nano sized. Nanotechnology essentially deals with design, manufacturing and characterization of nano sized particles 3 (*Website*, no date; Ashwini, Ezhilarasan and Anitha, 2017). Nanotechnology is associated with nanometer sized objects. Living organisms composed of cells. These cell parts however are nano sized. Nanotechnology he sincerely deals with them design manufacturing and characterisation or nano sized particles. Nanomedicine gives a chance to dental specialists to include more biomimetic substances in dental treatment so that there is more noteworthy coordination between the nanostructures supplanting the parts of the teeth with our body's regenerative process (Sriram, Vishnupriya and Gayathri, 2016). DNA antibodies evoke defensive CD 8+ immune system micro organism reaction. Malarial naive volunteers who were inoculated with plasmid DNA encoding a malarial protein create an antigen-explicit hereditary confined CD8+ lymphocytes subordinate CTLs. Reactions were coordinated against each of the 10 peptides tried and were limited by six human lymphocytes antigen (HLA) class one alleles (Wang, 1998; Ezhilarasan, Lakshmi, Nagaich, *et al.*, 2017).

Immunisation with DNA expressing the pre membrane and envelope proteins of ZIKV was immunogenic in the mice and subjects other than humans and protection against viremia after ZIKV. Challenge related with serum killing action (Dowd *et al.*, 2016). The strength of HIV DNA immunisation was improved by in vivo electroporation, as decided by expanded beginning, extent and term of counteracting agent Ansal interacted with a resistant reaction against Gaa and Env vaccine (Ahmad *et al.*, 1994). Galaxy WEBDock with TLR-2 receptor exhibit promising interactions for all epitopes with E2 and E3 having greatest hydrogen bond interactions (n = 13) followed by E1 (Girija *et al.*, 2020). Despite its numerous advantages, DNA antibody is restricted in its application by its lacking immunogenicity. One promising methodology for improving its immunogenicity is to expand its demeanor in the incubated host. They have harmful effects against DNA by production of inducing antibody production towards DNA itself. The caution should be taken so that the antibodies are not produced against DNA (Zhang and Nandakumar, 2018).

DNA VACCINE

DNA vaccine is the most promising strategy utilised up until this point, equipped for creating both humoral and cell mediated immunity. The proficiency of DNA vaccination can be improved by balancing out DNA into antigen- introducing cells DNA vaccinations are particularly significant instruments with colossal potential attributable to the molecular precision they offer (Ahmad *et al.*, 1994; Lakshmi *et al.*, 2015). The properties of the plasmid DNA atom as far as strength caused viability and absence of cold chain prerequisite or extra favourable circumstances over conventional antibodies and therapeutics (Zhang and Nandakumar, 2018). Traditional vaccine stimulates cell mediated immunity whereas DNA vaccination stimulates humoral immunity. DNA immunisation race neutralising antibody and cytotoxic T lymphocytes reactions and give some weakening of the intense period of the disease however it didn't forestall the loss of CD4+ cells (Richardson, 1996; Ashwini, Ezhilarasan and Anitha, 2017).

ADVANCES IN DNA VACCINE:

DNA vaccination atoms to intervene in autoimmune processes. The DNA immunisation raised both killing counter acting agent and cytotoxic T-lymphocytes reactions and gave some lessening of the intense period of contamination however it didn't forestall the loss of CD4+ cells. DNA vaccination particularly significant instruments with colossal potential attributable to The molecular position they offer. The properties of plasmid DNA atom as far as strength cost viability and absence of cold chain prerequisite are

extra favourable circumstances over conventional vaccinations and absence of cold chain prerequisite are extra favourable circumstances over conventional vaccination and therapeutics (Lu *et al.*, 1996; Ezhilarasan, Lakshmi, Vijayaragavan, *et al.*, 2017). Hepatitis C is one of the challenging infections everywhere throughout the world. Novaccine has been created. The HCV structural gene and the particles looks similar to viruses have been endeavoured this far the outcomes are promising in the experimental animals (Ullah, Shah and Riaz, 2012). Hepatitis B is an irresistible malady brought by the hepatitis B virus (HBV) which influences deliver. In a dental centre diseases can be transmitted through a few different ways including direct or in direct contact with blood and oral liquid vaporisers and so on (Pratha, Ashwatha Pratha and Geetha, 2017; Gheena and Ezhilarasan, 2019). Hepatic fibrosis is usually preceded by CLD and is an outcome from the progressive accumulation and reduced degradation or remodelling of extracellular matrix ECM any aetiology including viral infection alcoholic liver disease and non-alcoholic steatohepatitis ('Role of MicroRNAs in Hepatic Fibrosis Progression', 2018).

BENEFITS OF DNA VACCINE:

Immunotherapy can possibly give a potential treatment therapy to forestall or postpone Alzheimer ailment (Rezaei, Aghamohammadi and Notarangelo, 2016; Perumalsamy *et al.*, 2018). The DNA support overwhelmed in the lymphocytes safe reaction as it down directed antigen elicit immune system microorganisms level with what we have appeared previously and a peptide prime/DNA help routine is in this manner gainful as its limit the danger of a fiery invulnerable reaction (Lambracht-Washington *et al.*, 2011; Anitha and Ashwini, 2017). DNA vaccination with hAg 85B Evoked potent Th-1 like and cytotoxic T- cells immune reactions in BALB/c mice and created higher defensive invulnerability in a BALB/c mice of mycobacterium tuberculosis vaporised disease than did the antibody with wild type Ag85B (Hasnain, Ehtesham and Grover, 2019). Codon modification of Mycobacterial antigen could improve protein articulation and thereby upgrade the immunogenicity of DNA immunisation against Mycobacterium tuberculosis DNA coding and Mycobacterial antigens could improve protein accumulation and thereby upgrade the immunogenicity of DNA immunisation against Mycobacterium tuberculosis (Rezaei, Aghamohammadi and Notarangelo, 2016; Perumalsamy *et al.*, 2018). DNA encoding a mycobacterium antigen gives an effective and straightforward strategy for producing defensive invulnerability and that this methodology might be helpful for characterising the defensive antigens of Mycobacterium tuberculosis prompting the improvement of progressively successful antibody ('Genes encoding Mycobacterium tuberculosis protein antigens useful for tuberculosis vaccine preparation and therapy', 1989). Nasal tuberculosis infection may disseminate to maxillary palatal region by infectious or haematogenous course causing palatal aperture (Rajam, Kumar and Kumar, 2017; Mehta *et al.*, 2019)

PARTICLE MEDIATED MEDIATED DNA VACCINE:

Particle mediated epidermal delivery is a DNA vaccine delivery technology shown to elicit protective levels of antibody auncie cell responses in animals and humans at odds with a wide variety of infection. PMMA4 particles elicited the most significant level of TNF- α secretion by macrophages in vitro and yielded the best after effect of antitumor assurance in viva (Yang *et al.*, 2009). Particle mediated conveyance of DNA expression vector encoding hemagglutinin of H1N1 Flu infection to porcine epidermis evokes a humoral safe reaction and quickens the clearance of infection in pigs. Mucosal organisation of HA expression plasmid evokes a safe reaction that is subjectively not quite the same as that evoked by epidermal immunisation as far as hindrance of the underlying infection contamination (Shah *et al.*, 2014).

TRANSPORT OF DNA VACCINE :

Low molecular weight chit has a lesser binding affinity for DNA and mediated higher transfection efficiency. They are internalised by nasal epithelial cells intra nasal immunisation with LMWC / DNA polyplexes could evoke noteworthy fundamental immune reactions, balance them plasma lipoprotein

profile and constrict the movement of atherosclerosis. LMCs have potential application dispense by means of mucosa (Yang *et al.*, 2009). Small/short or silencing interfering RNA (siRNA) has possible therapeutic implication via post-transcriptional downregulation of the target gene expression. In chronic respiratory diseases, localised and targeted delivery of siRNA is attained via inhalation (Dua *et al.*, 2019). The use of nanotechnology in medicine particularly for drug delivery is known to have various benefits. Nanoparticles are being utilised to lessen harmful side-effects that drug may impose to the patient (Saravanabhavan *et al.*, 2019)

Role of nanoparticles in DNA vaccine:

Nanoparticles have recently become an essential prospect in the field of medicine due to their inquisitive properties and anti-cancer property. They are non-toxic bio compatible operators (Menon *et al.*, 2018; Rajeshkumar, Agarwal, *et al.*, 2018). Nano carrier drug delivery systems emerge as a promising perspective and is anticipated to give latest and advanced avenues in cancer therapeutics (Sharma *et al.*, 2019). The structure of upgraded nanoparticles offers a promising technique to empower DNA vaccines to cross different physiological boundaries for evoking a particular and defensive mucosal in susceptibility through intranasal organisation created nanoparticles offer a potential stage for DNA immunization bundling and dispensing for increasingly productive elicitation of mucosal immunity (Chen *et al.*, 2013). Nanotechnology is the advancement of engineered devices or materials at the smaller scale sub-atomic level the nanometer extent. It is the advancement of engineered devices or materials at the smaller scale sub-atomic level in the nanometer extent. There are conventional vaccines that failed to react adequately (Donnelly and Singh, 2015; Rajeshkumar, Venkat Kumar, *et al.*, 2018).

DNA vaccine against SARS-CoV

DNA vaccine encoding the spike (s) glycoprotein of SARS-CoV instigates and killing counter agent reactions, just as defensive resistance, in a mouse model. Elective types of SARS-CoV evokes powerful safe reactions that produce defensive resistance in the subjects (Yang *et al.*, 2004). N protein of SARS-CoV is a significant B cell immunogen, yet in addition can evoke wide based cell resistant reactions. N-proteins might be of potential incentive in antibody advancement for explicit prophylaxis and treatment against SARS (Zhao *et al.*, 2005; Ezhilarasan, Sokal and Najimi, 2018).

Test on the subjects:

Expression of the gene for a single mycobacterial antigen in adult Balb/c mice resulted in cell-mediated protection against M.tuberculosis. CD4 and CD8 T cells cloned from spleens of such inoculated mice latently moved protectivity to non-vaccinated mice (Lowrie, Silva and Tascon, 1998) Animals injected with pcDNA -SoD produces SOD-specific antibodies which showed a dominance of immune responses which showed a dominance of immunoglobulin G2a (Ig G2a) over IgG1. It was found from the studies that the BALB/C mice elicited a cellular immune responses and T-cell -proliferative response (Oñate *et al.*, 2003)

Limitations:

DNA vaccines are in their early phase, there are no DNA vaccine at the market at present. DNA vaccines or vaccines that are expected to be the vaccine of next generation

CONCLUSION:

DNA vaccines for human use assures consistent safety efficacy. It acts against HIV, hepatitis Zika virus valuable insights can be applied to influenza in future. Immunization with DNA encoding a mycobacterial antigen gives a productive and simple method for creating defensive immunity and that this procedure

might be helpful for characterizing the defensive antigens of *M.tuberculosis*, leading to the development of a more effective vaccine. The immunisation with DNA encoding mycobacterial antigen generates protective immunity. DNA vaccines are useful for defining protective antigens of *M. tuberculosis*. The DNA vaccine raised neutralising antibody, cytotoxic T-lymphocyte responses which provides attenuation acute phase of infection and failed to prevent the loss of CD4+ cells. It results in specific immune activation of the host against the gene delivered antigen. In future DNA vaccines can be applied to boost immune system.

AUTHOR CONTRIBUTION:

Idea was conceptualized by Lakshminarayanan Arivarasu and the manuscript was drafted by R.Pon Preeja.

CONFLICT OF INTERESTS:

The authors declare no conflict of interest.

REFERENCE:

- [1] Ahmad, S. *et al.* (1994) 'Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency Virus', *AIDS Research and Human Retroviruses*, pp. 195–204. doi: 10.1089/aid.1994.10.195.
- [2] Anitha, R. and Ashwini, S. (2017) 'Antihyperglycemic activity of *Caralluma fimbriata*: An In vitro approach', *Pharmacognosy Magazine*, p. 499. doi: 10.4103/pm.pm_59_17.
- [3] Ashwini, S., Ezhilarasan, D. and Anitha, R. (2017) 'Cytotoxic Effect of *Caralluma fimbriata* Against Human Colon Cancer Cells', *Pharmacognosy Journal*, pp. 204–207. doi: 10.5530/pj.2017.2.34.
- [4] Baker, J. R. *et al.* (2001) *Advances in Parasitology*. Greenwood Publishing Group.
- [5] Chen, L. *et al.* (2013) 'Enhanced Nasal Mucosal Delivery and Immunogenicity of Anti-Caries DNA Vaccine through Incorporation of Anionic Liposomes in Chitosan/DNA Complexes', *PLoS ONE*, p. e71953. doi: 10.1371/journal.pone.0071953.
- [6] Donnelly, R. F. and Singh, T. R. R. (2015) *Novel Delivery Systems for Transdermal and Intradermal Drug Delivery*. John Wiley & Sons.
- [7] Dowd, K. A. *et al.* (2016) 'Rapid development of a DNA vaccine for Zika virus', *Science*, 354(6309), pp. 237–240.
- [8] Dua, K. *et al.* (2019) 'The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress', *Drug development research*, 80(6), pp. 714–730.
- [9] Ezhilarasan, D., Lakshmi, T., Vijayaragavan, R., *et al.* (2017) 'Acacia catechu ethanolic bark extract induces apoptosis in human oral squamous carcinoma cells', *Journal of Advanced Pharmaceutical Technology & Research*, p. 143. doi: 10.4103/japtr.japtr_73_17.
- [10] Ezhilarasan, D., Lakshmi, T., Nagaich, U., *et al.* (2017) 'Acacia catechu ethanolic seed extract triggers apoptosis of SCC-25 cells', *Pharmacognosy Magazine*, p. 405. doi: 10.4103/pm.pm_458_16.
- [11] Ezhilarasan, D. (2018) 'Oxidative stress is bane in chronic liver diseases: Clinical and experimental perspective', *Arab journal of gastroenterology: the official publication of the Pan-Arab Association of Gastroenterology*, 19(2), pp. 56–64.
- [12] Ezhilarasan, D., Sokal, E. and Najimi, M. (2018) 'Hepatic Fibrosis: It Is Time to Go With Hepatic Stellate Cell-Specific Therapeutic Targets', *Hepatobiliary & pancreatic diseases international: HBPD INT*. Hepatobiliary Pancreat Dis Int, 17(3). doi: 10.1016/j.hbpd.2018.04.003.
- [13] 'Genes encoding Mycobacterium tuberculosis protein antigens useful for tuberculosis vaccine preparation and therapy' (1989) *Vaccine*, p. 161. doi: 10.1016/0264-410x(89)90062-5.

- [14] Gheena, S. and Ezhilarasan, D. (2019) 'Syringic acid triggers reactive oxygen species-mediated cytotoxicity in HepG2 cells', *Human & Experimental Toxicology*, pp. 694–702. doi: 10.1177/0960327119839173.
- [15] Girija, A. S. S. *et al.* (2020) 'Accessing the T-Cell and B-Cell Immuno-Dominant Peptides from A.baumannii Biofilm Associated Protein (bap) as Vaccine Candidates: A Computational Approach', *International Journal of Peptide Research and Therapeutics*. doi: 10.1007/s10989-020-10064-0.
- [16] Hasnain, S. E., Ehtesham, N. Z. and Grover, S. (2019) *Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions*. Springer Nature.
- [17] Huygen, K. *et al.* (1996) 'Immunogenicity and protective efficacy of a tuberculosis DNA vaccine', *Nature Medicine*, pp. 893–898. doi: 10.1038/nm0896-893.
- [18] Karthiga, P., Rajeshkumar, S. and Annadurai, G. (2018) 'Mechanism of Larvicidal Activity of Antimicrobial Silver Nanoparticles Synthesized Using Garcinia mangostana Bark Extract', *Journal of Cluster Science*, pp. 1233–1241. doi: 10.1007/s10876-018-1441-z.
- [19] Kumar, V. and Sercarz, E. (1996) 'Genetic vaccination: The advantages of going naked', *Nature Medicine*, pp. 857–859. doi: 10.1038/nm0896-857.
- [20] Lakshmi, T. *et al.* (2015) 'Azadirachta indica : A herbal panacea in dentistry - An update', *Pharmacognosy Reviews*, p. 41. doi: 10.4103/0973-7847.156337.
- [21] Lambracht-Washington, D. *et al.* (2011) 'DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer's Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation', *Cellular and Molecular Neurobiology*. doi: 10.1007/s10571-011-9680-7.
- [22] Lowrie, D. B., Silva, C. L. and Tascon, R. E. (1998) 'Progress Towards a New Tuberculosis Vaccine', *BioDrugs*, pp. 201–213. doi: 10.2165/00063030-199810030-00004.
- [23] Lu, S. *et al.* (1996) 'Simian immunodeficiency virus DNA vaccine trial in macaques', *Journal of virology*, 70(6), pp. 3978–3991.
- [24] Maheswari, T. N. U. *et al.* (2018) 'Salivary micro RNA as a potential biomarker in oral potentially malignant disorders: A systematic review', *Tzu Chi Medical Journal*, p. 55. doi: 10.4103/tcmj.tcmj_114_17.
- [25] Mehta, M. *et al.* (2019) 'Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases', *Chemico-Biological Interactions*, pp. 206–215. doi: 10.1016/j.cbi.2019.05.028.
- [26] Menon, S. *et al.* (2018) 'Selenium nanoparticles: A potent chemotherapeutic agent and an elucidation of its mechanism', *Colloids and Surfaces B: Biointerfaces*, pp. 280–292. doi: 10.1016/j.colsurfb.2018.06.006.
- [27] Oñate, A. A. *et al.* (2003) 'A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice', *Infection and Immunity*, pp. 4857–4861. doi: 10.1128/iai.71.9.4857-4861.2003.
- [28] Perumalsamy, H. *et al.* (2018) 'In silico and in vitro analysis of coumarin derivative induced anticancer effects by undergoing intrinsic pathway mediated apoptosis in human stomach cancer', *Phytomedicine: international journal of phytotherapy and phytopharmacology*, 46, pp. 119–130.
- [29] Pratha, A. A., Ashwatha Pratha, A. and Geetha, R. V. (2017) 'Awareness on Hepatitis-B vaccination among dental students-A Questionnaire Survey', *Research Journal of Pharmacy and Technology*, p. 1360. doi: 10.5958/0974-360x.2017.00240.2.
- [30] Rajam, L., Kumar, M. H. and Kumar, S. H. (2017) 'Primary Tuberculosis of Nose Causing Bilateral Nasal Obstruction and Halitosis in a 25-Year-Old Woman', *Journal of clinical and diagnostic research: JCDR*, 11(2), pp. ZD17–ZD18.

- [31] Rajeshkumar, S., Venkat Kumar, S., *et al.* (2018) 'Biosynthesis of zinc oxide nanoparticles using *Mangifera indica* leaves and evaluation of their antioxidant and cytotoxic properties in lung cancer (A549) cells', *Enzyme and Microbial Technology*, pp. 91–95. doi: 10.1016/j.enzmictec.2018.06.009.
- [32] Rajeshkumar, S., Agarwal, H., *et al.* (2018) 'Brassica oleracea Mediated Synthesis of Zinc Oxide Nanoparticles and its Antibacterial Activity against Pathogenic Bacteria', *Asian Journal of Chemistry*, pp. 2711–2715. doi: 10.14233/ajchem.2018.21562.
- [33] Rezaei, N., Aghamohammadi, A. and Notarangelo, L. D. (2016) *Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management*. Springer.
- [34] Richardson, C. C. (1996) 'Characterization and modification of phage T7 DNA polymerase for use in DNA sequencing. Final report, June 1, 1988--January 31, 1996'. doi: 10.2172/491398.
- [35] Robinson, H. L. and Pertmer, T. M. (2000) 'DNA vaccines for viral infections: Basic studies and applications', *Advances in Virus Research*, pp. 1–74. doi: 10.1016/s0065-3527(00)55001-5.
- [36] 'Role of MicroRNAs in Hepatic Fibrosis Progression' (2018) *Journal of Applied Pharmaceutical Science*. doi: 10.7324/japs.2018.8524.
- [37] Saravanabhavan, S. S. *et al.* (2019) 'Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice', *Materials Science and Engineering: C*, pp. 1459–1468. doi: 10.1016/j.msec.2019.02.047.
- [38] Services, N. R. C. W. D. C. (united S. D. of F. of I. A. P. *et al.* (1996) 'Nuclear Regulatory Commission issuances. Volume 43, No. 1, January 1996'. doi: 10.2172/210922.
- [39] Shah, M. A. A. *et al.* (2014) 'Nanoparticles for DNA Vaccine Delivery', *Journal of Biomedical Nanotechnology*, pp. 2332–2349. doi: 10.1166/jbn.2014.1981.
- [40] Sharma, P. *et al.* (2019) 'Emerging trends in the novel drug delivery approaches for the treatment of lung cancer', *Chemico-Biological Interactions*, p. 108720. doi: 10.1016/j.cbi.2019.06.033.
- [41] Sriram, K., Vishnupriya, V. and Gayathri, R. (2016) 'Review on the role of Nanotechnology in Dentistry and Medicine', *Research Journal of Pharmacy and Technology*, p. 1249. doi: 10.5958/0974-360x.2016.00236.5.
- [42] Ullah, S., Shah, M. A. A. and Riaz, N. (2012) 'Recent Advances in Development of DNA Vaccines Against Hepatitis C virus', *Indian Journal of Virology*, pp. 253–260. doi: 10.1007/s13337-012-0058-3.
- [43] Wang, R. (1998) 'Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine', *Science*, pp. 476–480. doi: 10.1126/science.282.5388.476.
- [44] *Website* (no date). Available at: Krishna, R. N., Gayathri, R., & Priya, V. (2017). Nanoparticles and their applications - A review. *Journal of Pharmaceutical Sciences and Research*, 9(1), 24-27. Retrieved from <https://search.proquest.com/docview/1867113824?accountid=176450> (Accessed: 7 June 2020).
- [45] Yang, X. *et al.* (2009) 'Low molecular weight chitosan in DNA vaccine delivery via mucosa', *International Journal of Pharmaceutics*, pp. 123–132. doi: 10.1016/j.ijpharm.2009.03.032.
- [46] Yang, Z.-Y. *et al.* (2004) 'A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice', *Nature*, pp. 561–564. doi: 10.1038/nature02463.
- [47] Zhang, N. and Nandakumar, K. S. (2018) 'Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases', *Vaccine*, pp. 3208–3220. doi: 10.1016/j.vaccine.2018.04.062.
- [48] Zhao, P. *et al.* (2005) 'Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine', *Virology*, 331(1), pp. 128–135.